A singe-blind, randomised, triple cross-over, single-dose pharmacokinetic and safety study of HTD1801 and its components.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2017
At a glance
- Drugs HTD 1801 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Pharmacokinetics
- Sponsors HighTide Biopharma
- 24 Jan 2017 Planned number of patients changed from 20 to 24.
- 24 Jan 2017 Planned initiation date changed from 14 Jan 2017 to 13 Feb 2017.
- 11 Jan 2017 New trial record